


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:


Listing of Claims:

1. (Currently Amended) A compound of Formula (1):



wherein:

Cy is a group of Formula (2):



C₃₋₇cycloalkyl or phenyl;

R₁, R₂, R₃, R₄ and R₅ are hydrogen, halogen, hydroxy, amino, trifluoromethyl or nitrile and at least one of R₁, R₂, R₃, R₄ and R₅ is halogen, trifluoromethyl or nitrile;

R₆ is hydrogen, optionally substituted straight-chained or branched C₁₋₃ alkyl, amino or hydroxy;

R₇ is hydrogen, optionally substituted straight-chained or branched C₁₋₃alkyl, ~~optionally substituted-amino~~
optionally substituted with one or more of the same or

different kinds of straight-chained or branched C₁₋₃ alkyl, or
hydroxy;

R₈ is hydrogen, methyl or ethyl;

R₉ is optionally substituted straight-chained or
branched C₁₋₆ alkyl, optionally substituted straight-chained or
branched C₂₋₆alkenyl, optionally substituted straight-chained
or branched C₂₋₆alkynyl, C₃₋₇cycloalkyl or optionally
substituted phenyl;


R₂₀ is hydrogen or straight-chained or branched
C₁₋₃alkyl or R₉ and R₂₀ may together form C₃₋₇cycloalkyl;

R₁₀ is hydrogen or straight-chained or branched
C₁₋₃alkyl;

R₁₁ is hydrogen, straight-chained or branched C₁₋₃
alkyl optionally substituted with one or more groups which may
be the same or different and are selected from the group
consisting of amino optionally substituted with one or more of
the same or different straight-chained or branched C₁₋₃ alkyl;
3- to 7-membered cyclic amino optionally substituted with
hydroxyl, amino, carboxyl, carbamoyl or methyl; hydroxyl,
methoxy, halogen, carbamoyl, methanesulfonyl, ureide,
guanidyl, N'-cyano-N''-methylguanidyl, sulfamoylamino,
carbamoylmethylamino and methanesulfonylamino, -CO-N(R₁₄)R₁₅,
carboxyl;

R₁₂ is hydroxy or -OR₁₆;

R₁₃ is hydrogen, straight-chained or branched C₁₋₆ alkyl, straight-chained or branched C₂₋₆alkenyl, straight-chained or branched C₂₋₆alkynyl or a group of Formula (3):



R₁₄ and R₁₅, which may be the same or different, are each hydrogen, straight-chained or branched C₁₋₃ alkyl optionally substituted with straight-chained or branched C₁₋₃ alkoxy optionally substituted with hydroxyl, amino, carboxyl or carbamoyl; hydroxyl; amino; methylamino; dimethylamino; carbamoyl or methanesulfonyl; optionally substituted straight-chained or branched C₁₋₄ alkyl, C₃₋₇cycloalkyl, straight-chained or branched C₁₋₄ alkoxy, straight-chained or branched C₁₋₄ alkylsulfonyl or a heterocyclic ring;

R₁₆ is straight-chained C₁₋₄ alkyl;

R₁₇ is hydrogen or methyl;

R₁₈ and R₁₉ together form cycloalkyl or C₃₋₇ cycloalkenyl;

X is carbonyl or methylene;

Y is carbonyl or methylene;

or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

2. (Currently amended) The compound according to claim 1,
wherein Cy in Formula (1) is a group of Formula (2);
or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

3. (Currently Amended) The compound according to claim 1,
wherein Cy in Formula (1) is a group of Formula (2) in which
at least one of R₁, R₂, R₃, R₄ and R₅ is halogen and the others
are hydrogen or hydroxy;
or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

4. (Currently Amended) The compound according to claim 1,
wherein Cy in Formula (1) is a group of Formula (2) in which
R₃ is halogen or R₂ and R₃ are the same kind of halogen;
or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

5. (Currently Amended) The compound according to claim 1,
wherein Cy in Formula (1) is a group of Formula (2) in which
R₃ is halogen and R₁, R₂, R₄ and R₅ are hydrogen, or R₂ and R₃
are the same kind of halogen and R₁, R₄ and R₅ are hydrogen;
or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

6. (Currently Amended) The compound according to claim 1,
wherein Cy in Formula (1) is a group of Formula (2) in which at least one of R₁, R₂, R₃, R₄ and R₅ is trifluoromethyl and the others are hydrogen, halogen or hydroxy;
or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

7. (Currently Amended) The compound according to claim 1,
wherein Cy in Formula (1) is a group of Formula (2) in which at least one of R₁, R₂, R₃, R₄ and R₅ is nitrile and the others are hydrogen, halogen or hydroxy;
or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

8. (Currently Amended) The compound according to claim 1,
wherein Cy in Formula (1) is a group of Formula (2) in which R₃ is trifluoromethyl;
or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

9. (Currently Amended) The compound according to claim 1,
wherein Cy in Formula (1) is a group of Formula (2) in which R₃ is nitrile;
or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

Claims 10-12. (Canceled)

13. (Currently Amended) The compound according to claim 1, wherein R_6 in Formula (1) is hydrogen or methyl; or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

14. (Currently Amended) The compound according to claim 1, wherein R_7 in Formula (1) is hydrogen or ~~optionally substituted amino~~ optionally substituted with one or more of the same of different kinds of straight-chained or branched C_{1-3} alkyl; or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

15. (Currently Amended) The compound according to claim 1, wherein R_8 in Formula (1) is hydrogen or methyl; or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

16. (Currently Amended) The compound according to claim 1, wherein R_9 in Formula (1) is methyl, isopropyl, isobutyl, sec-butyl, tert-butyl, 3-pentyl, neopentyl, cyclohexyl, phenyl, benzyl, para-hydroxybenzyl, cyclohexylmethyl or para-fluorobenzyl; or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

17. (Currently Amended) The compound according to claim 1, wherein R_{20} in Formula (1) is hydrogen or methyl; or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

18. (Currently Amended) The compound according to claim 1, wherein R_{10} in Formula (1) is hydrogen or methyl; or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

19. (Currently Amended) The compound according to claim 1, wherein R_{11} in Formula (1) is methyl, hydroxymethyl, carbamoylmethyl, methanesulfonylmethyl, ureidemethyl, sulfamoylaminomethyl, methanesulfonylaminomethyl, carbamoyl, ethylcarbamoyl, n-propylcarbamoyl, isopropylcarbamoyl, cyclopropylcarbamoyl, tertbutylcarbamoyl, methoxycarbamoyl, methylcarbamoyl, methanesulfonylmethylcarbamoyl, methoxymethylcarbamoyl,; or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

20. (Currently Amended) The compound according to claim 1, wherein R_{12} in Formula (1) is hydroxy; or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

21. (Currently Amended) The compound according to claim 1, wherein R_{13} in Formula (1) is isopropyl, tert-butyl (tBu), 1,1-dimethylpropyl or 1,1-dimethyl-2-propenyl; or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

22. (Currently Amended) The compound according to claim 1, wherein in Formula (1) Cy is a group of Formula (2)

in which at least one of R_1 , R_2 , R_3 , R_4 and R_5 is halogen and the others are hydrogen or hydroxy;

R_6 is hydrogen or methyl;

R_7 is hydrogen or ~~optionally substituted amino~~ optionally substituted with one or more of the same or different straight-chained or branched C_{1-3} alkyl;

R_8 is hydrogen or methyl;

R_9 is methyl, isopropyl, isobutyl, sec-butyl, tert-butyl, 3-pentyl, neopentyl, cyclohexyl, phenyl, benzyl, para-hydroxybenzyl, para-fluorobenzyl or cyclohexylmethyl;

R_{20} is hydrogen;

R_{10} is hydrogen or methyl;

R_{11} is methyl, hydroxymethyl, carbamoylmethyl, methanesulfonylmethyl, ureidemethyl, sulfamoylaminomethyl, methanesulfonylaminomethyl, carbamoyl, methylcarbamoyl, ethylcarbamoyl, n-propylcarbamoyl, isopropylcarbamoyl, cyclopropylcarbamoyl, tert-butylcarbamoyl, , methanesulfonylmethylcarbamoyl, methoxymethylcarbamoyl, or methoxycarbamoyl,;

R_{12} is hydroxy;

R_{13} is isopropyl, tert-butyl (tBu), 1,1-dimethylpropyl or 1,1-dimethyl-2-propenyl;

or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

23. (Currently Amended) The compound according to claim 1 which is selected from the group of compounds consisting of Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH₂, Phe(4-Cl)-N-Me-Val-N-Me-Tyr(3-tBu)-NH₂, Phe(3,4-F₂)-N-Me-Val-N-Me-Tyr(3-tBu)-NH₂, Phe(3-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH₂, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHOMe, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-tertbutyl-4-hydroxyphenyl)-1-(2-pyridylcarbamoyl)ethylamide, N-(2-(2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methyl-butrylamino)-3-(3-tBu-4-hydroxyphenyl)propyl)urea, N-(2-(2-(2-amino-3-(4-fluorophenylpropanoyl-N-methylamino)-3-methyl)butyrylamino)-3-(3-tertbutyl-4-hydroxyphenyl)propyl)sulfamide, N-[2-(3-tertbutyl-4-hydroxyphenyl)-1-(methanesulfonylaminomethyl)ethyl]-2-[N-(4-fluorophenylalanyloyl)methylamino]-3-methylbutanamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-carbamidemethylethylamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-methanesulfonylmethylethylamide, 2-(2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methyl-butrylamino)-3-(3-tBu-4-hydroxyphenyl)propanol, 2-(1-(2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-

methyl-butrylamino)-2-(3-tertbutyl-4-hydroxyphenyl)ethyl)-6-methyl-4-pyrimidinone, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-(1,3,4-oxadiazol-2-yl)ethylamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-(1,2,4-oxadiazol-5-yl)ethylamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-tertbutyl-4-hydroxyphenyl)-1-(thiazol-2-yl)ethylamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-(1,3,4-triazol-2-yl)ethylamide, Tyr(2-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH₂, Tyr(3-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH₂, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NH₂, N-Me-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NH₂, N-Et-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NH₂, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHMe, N-Me-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHMe, N-Et-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHMe, N-Me-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH₂, N-Et-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH₂, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHMe, N-Me-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHMe, N-Et-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHMe, Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NH₂, N-Me-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NH₂, N-Et-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NH₂, Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHMe, N-Me-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHMe, N-Et-

Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHMe, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHtBu, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHCH₂SO₂CH₃, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHET, N-Me-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHET, N-Et-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHET, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHCH₂OH, N-Me-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHCH₂OH, N-Et-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHCH₂OH, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHET, N-Me-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHET, N-Et-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHET, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHCH₂OH, N-Me-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHCH₂OH, N-Et-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHCH₂OH, Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHET, N-Me-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHET, N-Et-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHET, Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHCH₂OH, N-Me-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHCH₂OH, N-Et-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHCH₂OH, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHcPr, and Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHnPr Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHPr;


or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

24. (Previously Presented) A pharmaceutical composition containing an effective amount of the compound according to claim 1 as an active ingredient and an inert pharmaceutically acceptable carrier.

25. (Previously Presented) A motilin receptor antagonist composition containing an effective amount of the compound according to claim 1 and an inert pharmaceutically acceptable carrier.

Claims 26-27. (Cancelled)

28. (Currently Amended) A compound of Formula (4):



wherein


Cy, R₆, R₈, R₉, R₂₀, R₁₀, R₁₂, R₁₃, X and Y are as defined in claim 1;

R₇' is hydrogen, straight-chained or branched C₁₋₃ alkyl optionally having at least one protected substituent, amino optionally having at least one ~~protected~~ substituent of the same or different straight-chained or branched C₁₋₃ alkyl or protected hydroxyl;

R₁₁'' is hydrogen, ~~optionally substituted~~ straight-chained or branched C₁₋₃ alkyl optionally substituted with one or more groups which may be the same or different and are selected from the group consisting of amino optionally substituted with one or more of the same or different straight-chained or branched C₁₋₃ alkyl; 3- to 7-membered

cyclic amino optionally substituted with hydroxyl, amino, carboxyl, carbamoyl or methyl; hydroxyl; methoxy; halogen; carbamoyl; methanesulfonyl; ureide; guanidyl; N'-cyano-N''-methylguanidyl; sulfamoylamino; carbamoylmethylamino; and methanesulfonylamino, -CO-N(R₁₄)R₁₅, wherein R₁₄ and R₁₅ are as defined in claim 1, carboxyl, straight-chained or branched C₁₋₃alkyl having a protected amino;
or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

29. (Currently Amended) A compound of Formula (5):



wherein:


Cy, R₆, R₈, R₉, R₂₀, R₁₀, R₁₂, R₁₃, X and Y are as defined in claim 1;

R₇'' is hydrogen, straight-chained or branched C₁₋₃alkyl optionally having at least optionally protected substituent, amino optionally having at least one ~~optionally protected~~ substituents which are the same or different straight-chained or branched C₁₋₃ alkyl, or optionally protected hydroxy; and

R₁₁' is hydrogen, straight-chained or branched C₁₋₃alkyl optionally having at least one protected substituent_s which may be the same or different and are selected from the

group consisting of protected amino optionally substituted
with one or more straight--chained or branched C₁₋₃ alkyl;
protected 3- to 7-membered cyclic amino optionally substituted
with protected hydroxyl, protected amino, protected carboxyl
or protected carbamoyl; protected hydroxyl; protected
carbamoyl; protected ureide; protected guanidyl; protected N'-
cyano-N''-methylguanidyl; protected sulfamoylamino; protected
carbamoylmethylamino and protected methanesulfonylamino; τ -CO-
N(R₁₄)R₁₅ wherein R₁₄ and R₁₅ are as defined in claim 1, carboxyl
or a hydrate or pharmaceutically acceptable salt thereof.

30. (Currently Amended) A compound of Formula (6):



wherein:

R₈ is hydrogen, optionally-substituted straight-
chained or branched C₁₋₃ alkyl, optionally substituted amino,
or hydroxy;


R₉, is optionally-substituted straight-chained or
branched C₁₋₆ alkyl, optionally substituted straight-chained or
branched C₂₋₆ alkenyl, optionally substituted straight-chained
or branched C₂₋₆ alkynyl, C₃₋₇ cycloalkyl or optionally
substituted phenyl;

R₂₀ is hydrogen or straight-chained or branched C₁₋₃ alkyl; or R₉ and R₂₀ may together form C₃₋₇ cycloalkyl;

R₁₀ is hydrogen or straight-chain or branched C₁₋₃ alkyl;

R₁₂ is hydroxy or OR₁₆;

R₁₃ is hydrogen, straight-chained or branched C₁₋₆ alkyl, straight-chained or branched C₂₋₆ alkenyl, straight-chained or branched C₂₋₆ alkynyl or a group of Formula (3)



Wherein R₁₇ is hydrogen or methyl;

R₁₈ and R₁₉ together form cycloalkenyl or C₃₋₇ cycloalkenyl; and

Y is carbonyl or methylene;

P₁ is hydrogen or a protecting group of amine; and

R₁₁''' is hydrogen, ~~optionally substituted~~ straight-chained or branched C₁₋₃alkyl, carboxyl, straight-chained or branched C₁₋₃alkyloptionally substituted with one or more groups which may be the same or different and are selected from the group consisting of amino optionally substituted with one or more of the same or different straight-chained or branched C₁₋₃ alkyl; 3- to 7-membered cyclic amino optionally substituted with hydroxyl, amino, carboxyl, carbamoyl or methyl; hydroxyl; methoxy; halogen; carbamoyl; methanesulfonyl; ureide;

guanidyl; N'-cyano-N''-methylguanidyl; sulfamoylamino;
carbamoylmethylamino and methanesulfonylamino; carboxyl,
straight-chained or branched C₁₋₃ alkyl having protected amino
or an optionally substituted heterocyclic ring, or -CO-
N(R₁₄)R₁₅ wherein R₁₄ and R₁₅, which may be the same or
different, are hydrogen, optionally substituted straight-
chained or branched C₁₋₄ alkyl, C₃₋₇ cycloalkyl, straight-
chained or branched C₁₋₄ alkoxy, straight-chained or branched
C₁₋₄alkylsulfonyl or a heterocyclic ring, ~~carboxyl, straight-~~
~~chained or branched C₁₋₃alkyl having protected amino or an~~
~~optionally substituted heterocyclic ring;~~
or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

Claims 31-34. (Canceled)

35. (Previously Presented) The compound according
to claim 1, wherein the substitution of the optionally
substituted straight-chained or branched C₁₋₃ alkyl as R₇ in
formula (1) is halogen, hydroxyl or amino.